Exagen
Exagen Q1 Revenues Drop 2 Percent
Testing revenues grew slightly during the quarter, driven by an increase in Avise test orders.
Exagen, QMUL to Develop Molecular Signatures for Rheumatoid Arthritis Therapy Selection
The assays under development will segment patients according to gene expression in their synovial tissue biopsies to personalize therapy selection.
Exagen Q3 Revenues Rise 14 Percent
The firm's testing revenues grew to $11.9 million, up 25 percent compared to the previous year's quarter. Its flagship Avise CTD test generated $9.9 million in revenues.
In Brief This Week: PerkinElmer, Fujirebio Europe, Exagen, Genetic Technologies, and More
News items for the in vitro diagnostics industry for the week of Oct. 25, 2021.
Exagen Enters $27.2M Debt Refinancing Agreement
The term loan agreement with Innovatus Life Sciences Lending was originally inked in 2017, with an amendment in 2019.
Aug 9, 2021
Exagen Posts 43 Percent Increase in Q2 Revenues
May 11, 2021
Exagen Q1 Revenues Grow 10 Percent
Mar 23, 2021
Exagen Prices $60.1M Public Offering of Stock
May 11, 2020
Exagen Q1 Revenues Grow 3 Percent
Nov 25, 2019
Nov 12, 2019
Exagen Q3 Revenues Rise 27 Percent
Oct 14, 2019